{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:24:30Z","timestamp":1782602670972,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1969-3","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T21:08:22Z","timestamp":1450300102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Trastuzumab-induced corneal ulceration: successful no-drug treatment of a \u201cblind\u201d side effect in a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"A.","family":"Orlandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fasciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Agresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Calegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Caporossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,16]]},"reference":[{"key":"1969_CR1","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"E Ramond","year":"2005","unstructured":"Ramond E, Perez A, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384.","journal-title":"N Engl J Med."},{"key":"1969_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"M Piccart","year":"2005","unstructured":"Piccart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372.","journal-title":"N Engl J Med."},{"key":"1969_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"D Slamon","year":"2001","unstructured":"Slamon D, Leyland B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer overexpress HER2. N Engl J Med. 2001;344:783\u201392.","journal-title":"N Engl J Med."},{"issue":"14","key":"1969_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eirmann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer (BCIRG 006 study). N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"issue":"9742","key":"1969_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"5","key":"1969_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10637-005-2899-8","volume":"23","author":"CH Yeon","year":"2005","unstructured":"Yeon CH, Pegram MD. Anti-ERB2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23(5):391\u201340.","journal-title":"Invest New Drugs"},{"issue":"3","key":"1969_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.breast.2003.09.002","volume":"13","author":"T Suter","year":"2004","unstructured":"Suter T, Cook-Bruns N, Barton C. Cadiotoxicity associeted with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13(3):173\u201383.","journal-title":"Breast"},{"issue":"6","key":"1969_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2146\/ajhp050549","volume":"63","author":"SF Wong","year":"2006","unstructured":"Wong SF. Trastuzumab and cardiotoxicity: weighing the risks. Am J Health Syst Pharm. 2006;63(6):525.","journal-title":"Am J Health Syst Pharm"},{"issue":"3 Suppl 11","key":"1969_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/sonc.2002.34051","volume":"29","author":"JW Schneider","year":"2002","unstructured":"Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol. 2002;29(3 Suppl 11):22\u20138.","journal-title":"Semin Oncol"},{"key":"1969_CR10","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"M Olayioye","year":"2000","unstructured":"Olayioye M, Neve R, Lane H, Hynes N. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159\u201367.","journal-title":"EMBO J"},{"key":"1969_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1677\/erc.0.0080011","volume":"8","author":"N Prenzel","year":"2001","unstructured":"Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family asa a central elelment for cellular signal trasduction and diversification. Endocr Relat Cancer. 2001;8:11\u201331.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1969_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","volume":"20","author":"Z Liu","year":"2001","unstructured":"Liu Z, Carvajal M, Carraway CA, Carraway K, Pflugfelder S. Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2 and ErbB3 in Human ocular surface epithelia. Cornea. 2001;20(1):81\u20135.","journal-title":"Cornea"},{"issue":"7","key":"1969_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/j.1755-3768.2012.02518.x","volume":"91","author":"WL1 Ho","year":"2013","unstructured":"Ho WL1, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol. 2013;91(7):604\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"1969_CR14","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M1 Untch","year":"2010","unstructured":"Untch M1, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28(12):2024\u201331.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1969_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris 3rd HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398\u2013405.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1969_CR16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/j.1346-8138.1992.tb03759.x","volume":"19","author":"S Kinoshita","year":"1992","unstructured":"Kinoshita S. Clinical application of epidermal growth factor in ocular surface disorders. J Dermatol. 1992;19(11):680\u20133.","journal-title":"J Dermatol"},{"issue":"5","key":"1969_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1006\/exer.2000.0979","volume":"72","author":"Y Nakamura","year":"2001","unstructured":"Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001;72(5):511\u20137.","journal-title":"Exp Eye Res"},{"issue":"12","key":"1969_CR18","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1167\/iovs.04-0119","volume":"45","author":"X Ke-Ping","year":"2004","unstructured":"Ke-Ping X, April R, Yu D, Fu-Shin XY. Role of ErbB2 in corneal epithelial wouund healing. Invest Opthalmol Vis Sci. 2004;45(12):4277\u2013428.","journal-title":"Invest Opthalmol Vis Sci"},{"issue":"2","key":"1969_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109\u201319.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1969-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T21:58:07Z","timestamp":1475791087000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1969-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1969"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1969-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"973"}}